

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/537,455	
			Filing Date	October 31, 2005	
			First Named Inventor	Bruce R. Zetter	
			Art Unit	1634	
			Examiner Name	Myers, Carla J	
Sheet	1	of	2	Attorney Docket Number	CMC-009

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
/CM	B2	WO-/97/48805	12-24-1997	Children's Medical Center		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/CM	C3	Aspinall JO, Bentel JM, Horsfall DJ, Haagensen DE, Marshall VR, Tilley WD, Differential expression of apolipoprotein-D and prostate specific antigen in benign and malignant prostate tissues, <i>J Urol.</i> 1995; 154:622-8.		
	C4	Blood CH, Zetter BR, Tumor interactions with the vasculature: angiogenesis and tumor metastasis, <i>Biochim Biophys Acta.</i> 1990; 1032(1):89-118.		
	C5	Boring CC, Squires TS, Tong T, Montgomery S, Cancer statistics, <i>CA Cancer J Clin.</i> 1994; 44(1):7-26.		
	C6	Caplan A, Kratz A, Prostate-specific antigen and the early diagnosis of prostate cancer, <i>Am J Clin Pathol.</i> 2002; 117 Suppl 1:S104-8.		
	C7	Catalona WJ, et al., Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men, <i>J Urol.</i> 1994; 151(5):1283-90.		
	C8	Cookson MS, Floyd MK, Ball TP, Miller EK, Sarosdy MF, The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels, <i>J Urol.</i> 1995; 154(3):1070-3.		
	C9	Fidler IJ, Gersten DM, Hart IR, The biology of cancer invasion and metastasis, <i>Adv Cancer Res.</i> 1978; 28:149-250.		
	C10	Fidler IJ, Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis, <i>Cancer Metastasis Rev.</i> 1986; 5(1):29-49.		
	C11	Haemmerli G, Sträuli P, In vitro motility of cells from human epidermoid carcinomas. A study by phase-contrast and reflection-contrast cinematography, <i>Int J Cancer.</i> 1981; 27(5):603-10.		
	C12	Hosaka S, Suzuki M, Goto M, Sato H, Motility of rat ascites hepatoma cells, with reference to malignant characteristics in cancer metastasis, <i>Gann.</i> 1978; 69(2):273-6.		
	C13	Liotta LA, Stracke ML, Tumor invasion and metastases: biochemical mechanisms, <i>Cancer Treat Res.</i> 1988; 40:223-38.		
	C14	Nicolson GL, Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites, <i>Biochim Biophys Acta.</i> 1988; 948(2):175-224.		

Examiner Signature	/Carla Myers/	Date Considered	11/06/2007
--------------------	---------------	-----------------	------------

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/537,455
				Filing Date	October 31, 2005
				First Named Inventor	Bruce R. Zetter
				Art Unit	1634
				Examiner Name	Myers, Carla J
Sheet	2	of	2	Attorney Docket Number	CMC-009


<div style="text-align: center;"> /CM/ ↓ ↓ ↓ ↓ </div>	C15	Woolf SH, The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound: a review of published scientific evidence, <i>Int J Technol Assess Health Care</i> . 2001; 17(3):275-304.	
	C16	Zetter BR, The cellular basis of site-specific tumor metastasis, <i>N Engl J Med</i> . 1990; 322(9):605-12.	
	C17	Hillier, et al., 1995, unpublished, genebank accession R08518.	
	C18	Yokoyama, M., et al., D82345: Homo sapiens mRNA for NB Thymosin Beta, Complete CDS on NCBI (1999).	
	C19	International Search Report for PCT/US04/004447 mailed on January 31, 2005	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Carla Myers/	Date Considered	11/06/2007
--------------------	---------------	-----------------	------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Substitute for form 1449 PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/537,455		
		Filing Date	I.A. 09 January 2004		
		First Named Inventor	ZETTER, Bruce et al.		
		Art Unit	To be assigned		
		Examiner Name	To be assigned		
Sheet	1	of	1	Attorney Docket Number	701039-050025-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
/CM/	A1	US 6,150,117	11/21/00	Zetter, Bruce et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	B1	JP 08004717	7/29/00	Yokoyama et al.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
/CM/	C1	SHOU et al., "Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression." <i>Proceedings of the National Academics of Science, USA. March 5, 2002, Vol. 99, No. 5; 2830-2835</i>	
/CM/	C2	YOKOYAMA, M., et al. "Identification and Cloning of Neuroblastoma-Specific and Nerve Tissue-Specific Genes through Compiled Expression Profiles." <i>DNA Research</i> , 1996, 3: 311-320	
		/Carla Myers/	Date Considered 11/06/2007

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.